On June 26, PegBio Pharmaceutical-B declined 8.19% in regular trading, trading at HK$5.25 per share, with turnover of approximately HK$41.46 million.

On the news front, the company announced the completion of its H-share full circulation. Approximately 101.7 million non-listed shares were converted into H shares on June 25, and began trading on the Hong Kong Stock Exchange at 9:00 a.m. on June 26. Following the conversion, the number of H shares increased from 284.3 million to 386.0 million, raising the H-share proportion from 72.69% to 98.70% of total issued shares. Non-listed shares dropped sharply from 106.8 million to just 5.09 million, representing only 1.30% of total capital. The concentrated release of previously restricted shares into the open market significantly expanded tradable supply, creating substantial short-term selling pressure on the stock price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)